1. HBW Insight
  2. >>Archive

Research & Development In Brief: Low-dose Aspirin, Cancer Risk | Probiotics, GI Issues For Austistic Kids

 
• By Elizabeth Crawford

Low-dose aspirin reduces colorectal cancer risk; probiotics ease GI problems in autistic children; resveratrol could cancel exercise benefits; and TCM product does not benefit stroke victims.

Taking low-dose aspirin every other day long-term might reduce the risk of colorectal cancer in healthy women, according to a July 15 study in the Annals of Internal Medicine. Researchers at Brigham and Women’s Hospital, Harvard Medical School and Harvard School of Public Health in Boston found Women’s Health Study participants who took low-dose aspirin every other day for at least 10 years and some as long as 18 years were 42% less likely to develop colon cancer than those in the placebo group. The benefit did not extend to other types of cancer. The researchers examined the use of aspirin on alternate days in part because most studies look at daily use, which poses adverse effects. The more restricted dose in this study still caused more cases of gastrointestinal bleeding than in the placebo group (8.3% vs. 7.3%) and peptic ulcers (7.3% vs. 6.2%).

The discovery that the cancer prevention benefits increase with longer use could prompt the U.S. Preventive Services Task Force to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

FTC Consumer Privacy Policy Driven By ‘Straw Man’ Arguments – Commissioner Holyoak

 
• By Eileen Francis

The US FTC’s contention that ‘notice and choice’ has failed as the cornerstone of consumer privacy regulation and must be abandoned in favor of data minimization and other more stringent measures does not adequately account for the complexity of business practices and consumer behavior, FTC commissioner Melissa Holyoak asserted at the NAD’s 2024 Annual Conference.

FTC’s New Commissioner ‘Dismayed’ By Agency Overreach

 
• By Eileen Francis

FTC Commissioner Melissa Holyoak says the agency has acted outside the bounds afforded by Congress, citing several areas within consumer protection, including a recent update to the final rule for the Health Breach Notification Rule and the commission’s use of notices of penalty offense to serve as the basis for Section 5 settlements. 

Beauty Brands Not On TikTok Shop ‘Really Missing Out’ – KO-Pack

 
• By Eileen Francis

At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

More from HBW Insight

Haleon Opens Start-Of-The-Art Oral Care R&D Facility In The UK

 
• By David Ridley

Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”

OLLY’s Lovin’ Libido Claims Score Support With Studies Of Women Reporting ‘Generally Low’ Desire

 
• By Malcolm Spicer

NAD reports the populations of six of seven RCTs Olly referenced as evidence were key in substantiating claims for Lovin’ Libido ashwagandha supplement challenged by Bayer. Supplement industry, though, is challenging the FTC’s RCT standard for claims support.

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By David Ridley

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.